Table 2.
Clinical and pathological characteristics of 497 GIST patients
| Age (years) | |
| Median | 60 |
| Range | 23-90 |
| Sex, n (%) | |
| Male | 278 (55.9) |
| Female | 219 (44.1) |
| Primary site of tumor, n (%) | |
| Stomach | 293 (59.0) |
| Duodenum | 31 (6.2) |
| Small bowel | 112 (22.5) |
| Large bowel | 4 (0.8) |
| Rectum | 21 (4.2) |
| Esophagus | 3 (0.6) |
| Other (omentum, mesenterium and retroperitoneum ) | 33 (6.6) |
| Clinical manifestation, n (%) | |
| Abdominal discomfort | 184 (37.0) |
| GI bleeding | 142 (28.6) |
| Diagnosed at physical examination | 81 (16.3) |
| Abdominal mass | 14 (2.8) |
| Other (fever, fatigue, appetite and explored at surgery for other diseases) | 76 (15.3) |
| IM therapy | |
| As adjuvant therapy for primary disease | 96 |
| As therapy for advanced disease (recurrent, metastatic, unresectable, or incomplete resected) | 46 |
| Immunohistochemistry, n (%) | |
| CD117 | 434 (87.3) |
| CD34 | 399 (80.3) |
| SMA | 119 (23.9) |
| S-100 | 107 (21.5) |
| DOG1 | 139 (93.3)* |
*DOG1 was examined in 165 cases.